<DOC>
	<DOCNO>NCT02206178</DOCNO>
	<brief_summary>Acetaminophen one widely use analgesic world , recommend symptomatic treatment fever pain . The purpose study assess effectiveness acetaminophen association N-acetylcysteine . The objective study evaluate association healthy volunteer acetaminophen N-acétylcystéine 1 . - decrease antinociceptive effect acetaminophen comparison group control 2 . - antinociceptive effect may depend genetic polymorphism GSH enzyme .</brief_summary>
	<brief_title>Acetaminophen 's Antinociceptive Effect When Associated With N-Acetylcysteneine</brief_title>
	<detailed_description>Period 1 : To Day -4 Day 0 Day -4 8:00 Clinical Pharmacology Center - Inclusion Visit , signature Informed consent form , clinical exam . - Training test - Blood sample ( GSH , pharmacogenetic , Biochemistry assay ) - Randomization attribution treatment fisrt study period home : ( day -4 , -3 , -2 , -1 ) 4 day oral acetaminophen [ N-acetylcysteine placebo ] accord randomization plan . At day -3 , -2 -1 salivary sample do control treatment compliance . Day 0 Clinical Pharmacology Center Clinical examination Measurement basal pain threshold pain evaluation ( Visual Analog Scales ) Blood urinary sample ( acetaminophen GSH assay ) T0 : Administration product : acetaminophen [ N-acetylcysteine placebo ] T0+1H : Thermal stimulation accord establish paradigm ( threshold temperature +3°C ) pain evaluation ( Visual Analog Scales ) T0+2H : Thermal stimulation accord establish paradigm ( threshold temperature +3°C ) pain evaluation ( Visual Analog Scales ) Blood sample ( acetaminophen assay ) T0+3H : Thermal stimulation accord establish paradigm ( threshold temperature +3°C ) pain evaluation ( Visual Analog Scales ) T0+4H : Thermal stimulation accord establish paradigm ( threshold temperature +3°C ) pain evaluation ( Visual Analog Scales ) Blood urinary sample ( acetaminophen , GSH , biochemistry assay ) - Lunch departure 2 week wash-out Period 2 : To Day 17 Day 21 Same period 1 . Subject receive N-acétylcystéine period 1 receive placebo second period vice versa .</detailed_description>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Male Between 18 45 year old Without treatment 7 day inclusion specially use antalgic antiinflammatory Cooperation understand enough conform study obligation Having give free , informed write consent Affiliated system French social security Inscription acceptation inscription national register volunteer involve trial . Patient one many contraindication administration trial 's product , Patient take Nacetylcysteine bronchial thinner last 3 day , Patient medical surgical history judge investigator representative compatible clinical trial Patient disease progression inclusion , Patient excessive consumption alcohol , tobacco ( + 10 cigarette/day ) , coffee , tea drink caffeine ( equivalent 4 cup day ) addiction drug , Patient heat pain mean threshold training high equal 46.5°C , Patient participate another clinical trial , locate exclusion period receive benefit &gt; 4500 euro 12 month begin trial , Patient cooperation understand allow follow trial , Patients minor guardianship , No affiliation system French social security</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>